PHAT

Phathom Pharmaceuticals, Inc. [PHAT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PHAT Stock Summary

Top 10 Correlated ETFs

PHAT

Top 10 Correlated Stocks

PHAT

In the News

PHAT Financial details

Company Rating
-
Market Cap
592.96M
Income
-201.45M
Revenue
682K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
452
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-2.55
Forward P/E
-
PEG
0.8
P/S
-
P/B
-26.61
P/C
-
P/FCF
-3.51
Quick Ratio
8.91
Current Ratio
9.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.88
EPS next Y
-
EPS next Q
-
EPS this Y
-31.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
82.89%
-
-
-
-
SMA20
-
SMA50
25%
SMA100
66.67%
Inst Own
-
Inst Trans
-
ROA
-78%
ROE
449%
ROC
-0.68%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.065-17.019
52W High
-5.35%
52W Low
+168.17%
RSI
63
Rel Volume
0.65
Avg Volume
917.88K
Volume
598.91K
Perf Week
10.58%
Perf Month
23.39%
Perf Quarter
81.81%
Perf Half Y
51.22%
-
-
-
-
Beta
0.627
-
-
Volatility
0.52%, 0.52%
Prev Close
4.75%
Price
16.09
Change
5.37%

Something similar

Top by Market Cap
AVGO
V
NVDA
GOOG
0YXG.L
Top Correlated ETFs
IXJ
PPH
XLV
FTXG
IYH
Top Correlated Stocks
TBPH
8835.T
2288.T
3103.T
BKD
Similar Market Cap
FMFAX
GAIN
002656.SZ
BKMC
JEMA

Company Profile

Healthcare Biotechnology
  • Volume Average 917.88K
  • Market Capitalization 592.96M
  • Employee 452
  • CEO Ms. Terrie J. Curran
  • Headquarters Florham Park,NJ,US
  • IPO Date 2019-10-25
  • Website https://www.phathompharma.com

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.